New York  London  GMT  Tokyo  Singapore 
Zacks Investment Research

Onyx Pharmaceuticals (ONXX) - Bull Of The Day

By Zacks Investment Research on February 25, 2009 | More Posts By Zacks Investment Research | Author's Website

Nexavar sales in the fourth quarter of 2008 remained strong for Onyx Pharmaceuticals, Inc. (ONXX). This is mainly attributed to the market penetration in the liver cancer market, while Nexavar market share in kidney cancer market has stabilized due to heavy competition from Pfizer (PFE) and Wyeth (WYE).

We expect continued Nexavar sales growth in 2009 and over the next several years since the label has expanded to liver cancer. In addition to the US and EU, Nexavar has been approved in South Korea and China for liver cancer.

Nexavar will achieve blockbuster status in 2010. We maintain our Buy rating on Onyx shares with a price target of $45 per share.

If you like this article please...
Subscribe by RSS Subscribe by Email Email This Post To A Friend Email This Post To A Friend

Leave A Comment :

Name (required)
E-mail (required - never shown publicly)
URI
Subscribe to comments via email
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> in your comment.
Opinions From Our Contributors
Commodities Financials Exchange Traded Funds
Stocks Forex Economy



HEADLINES
UPCOMING EVENTS
In 1 hr: CHF Money Supply M3 (YoY) (OCT)
In 1 hr: EUR French Purchasing Manager Index Manufacturing (NOV P)
In 1 hr: EUR French Purchasing Manager Index Services (NOV P)
In 2 hrs: EUR German Purchasing Manager Index Manufacturing (NOV A)
In 2 hrs: EUR German Purchasing Manager Index Services (NOV A)
Enter Your Email Address
Theme By: WordPress Theme Shop